專技 - 調劑學與臨床藥學題庫下載題庫

(A)看是使用哪種(***注意單位)

     filgrastim(G-CSF): 5mcg/kg

     peglyated G-CSF: 6mg/cycle

    sargramostim(GM-CSF): 250mcg/mm2

(B)給法

     filgrastim(G-CSF): 在化療前後24hr停藥

     peglyated G-CSF: 在化療前14天道化療後24hr停藥

(D)看情況

-CSF should not be used routinely in patients with neutropenia who are afebrile (ASCO Strong recommendation, High-quality evidence)-consider CSF for patients with fever and neutropenia at high risk for infection-associated complications or who have prognostic factors predictive of poor clinical outcomes, including (ASCO Strong recomm...
查看完整內容

(A)看是使用哪種(***注意單位)

     filgrastim(G-CSF): 5mcg/kg

     peglyated G-CSF: 6mg/cycle

    sargramostim(GM-CSF): 250mcg/mm2

(B)給法

     filgrastim(G-CSF): 在化療前後24hr停藥

     peglyated G-CSF: 在化療前14天道化療後24hr停藥

(D)看情況

• -CSF should not be used routinely in patients with neutropenia who are afebrile (ASCO Strong recommendation, High-quality evidence)
• -consider CSF for patients with fever and neutropenia at high risk for infection-associated complications or who have prognostic factors predictive of poor clinical outcomes, including (ASCO Strong recommendation, High-quality evidence)
  • 1.expected prolonged (> 10 days) and profound (< 0.1 × 10⁹/L) neutropenia
  • 2.>65 years old
  • 3.uncontrolled primary disease
  • 4.pneumonia
  • 5.hypertension and multiorgan dysfunction (sepsis syndrome)
  • 6.invasive fungal infection
  • 7.hospitalization at time of fever development

ref: DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995 - . Record No. T903015, Febrile Neutropenia; [updated 2019 Jul 17, cited]